ICCC vs. NYMX, TRIB, AWH, OCX, BMRA, CDIO, MYMD, TKNO, ACHV, and PLAG
Should you be buying ImmuCell stock or one of its competitors? The main competitors of ImmuCell include Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Aspira Women's Health (AWH), OncoCyte (OCX), Biomerica (BMRA), Cardio Diagnostics (CDIO), MyMD Pharmaceuticals (MYMD), Alpha Teknova (TKNO), Achieve Life Sciences (ACHV), and Planet Green (PLAG). These companies are all part of the "medical" sector.
ImmuCell vs.
ImmuCell (NASDAQ:ICCC) and Nymox Pharmaceutical (NASDAQ:NYMX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, community ranking, profitability, earnings and analyst recommendations.
12.6% of ImmuCell shares are owned by institutional investors. Comparatively, 0.8% of Nymox Pharmaceutical shares are owned by institutional investors. 6.3% of ImmuCell shares are owned by insiders. Comparatively, 54.0% of Nymox Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Nymox Pharmaceutical had 1 more articles in the media than ImmuCell. MarketBeat recorded 1 mentions for Nymox Pharmaceutical and 0 mentions for ImmuCell. ImmuCell's average media sentiment score of 0.00 equaled Nymox Pharmaceutical's average media sentiment score.
Nymox Pharmaceutical has a net margin of 0.00% compared to ImmuCell's net margin of -33.23%. ImmuCell's return on equity of -17.30% beat Nymox Pharmaceutical's return on equity.
ImmuCell has higher revenue and earnings than Nymox Pharmaceutical. Nymox Pharmaceutical is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.
Nymox Pharmaceutical received 29 more outperform votes than ImmuCell when rated by MarketBeat users. However, 73.33% of users gave ImmuCell an outperform vote while only 51.72% of users gave Nymox Pharmaceutical an outperform vote.
ImmuCell has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Nymox Pharmaceutical has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.
Summary
ImmuCell beats Nymox Pharmaceutical on 8 of the 14 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ICCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmuCell Competitors List
Related Companies and Tools
